Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes - 06/06/19
Doi : 10.1016/j.jaci.2019.02.013
Oliver P. Skinner, BSc a, Julie Jurczyluk, BSc a, Paul J. Baker, PhD b, Seth L. Masters, PhD b, Alicia G. Rios Wilks, BSc a, Misaki S. Clearwater, BSc a, Avril A.B. Robertson, PhD, MChem, GCHEd c, Kate Schroder, PhD d, Sam Mehr, MBBS, BMedSci, FRCPA, FRACP e, Marcia A. Munoz, PhD a, ∗, Michael J. Rogers, PhD a, ∗ 
a Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
b Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
c School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
d Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
e Department of Allergy/Immunology, Royal Children's Hospital, Melbourne, Australia
| Supported in part by NHMRC project grant APP1139644 (to M.J.R.), a grant from the Allergy and Immunology Foundation of Australasia (to M.A.M. and M.J.R.), Mrs Janice Gibson and the Ernest Heine Family Foundation, and the Marian & E.H. Flack Trust. |
|
| Disclosure of potential conflict of interest: A. A. B. Robertson and K. Schroder are coinventors on patent applications for NLRP3 inhibitors, which have been licensed to Inflazome, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. K. Schroder served on the Scientific Advisory Board of Inflazome in 2016-2017. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 6
P. 2315 - juin 2019 Retour au numéro
Article précédent
- Lymphoproliferative disease in patients with Wiskott-Aldrich syndrome: Analysis of the French Registry of Primary Immunodeficiencies
- Morgane Cheminant, Nizar Mahlaoui, Céline Desconclois, Danielle Canioni, Loïc Ysebaert, Loïc Dupré, Zilton Vasconcelos, Marion Malphettes, Despina Moshous, Bénédicte Neven, Pierre-Simon Rohrlich, Marc Bernard, Yves Bertrand, Alain Fischer, Felipe Suarez
- F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects
- Enrica Calzoni, Craig D. Platt, Sevgi Keles, Hye Sun Kuehn, Sarah Beaussant-Cohen, Yu Zhang, Julia Pazmandi, Gaetana Lanzi, Francesca Pala, Azzeddine Tahiat, Hasibe Artac, Raul Jimenez Heredia, Jasmin Dmytrus, Ismail Reisli, Vedat Uygun, Dilara Uygun, Aysen Bingol, Erdem Basaran, Kamel Djenouhat, Nafissa Benhalla, Chafa Bendahmane, Melike Emiroglu, Tomas Kirchhausen, Mithun Pasham, Jennifer Jones, Jacqueline G. Wallace, Lixin Zheng, Bertrand Boisson, Fulvio Porta, Sergio D. Rosenzweig, Helen Su, Silvia Giliani, Michael Lenardo, Raif S. Geha, Kaan Boztug, Janet Chou, Luigi D. Notarangelo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?